Clinical trials: Moderate-to-severe Ulcerative Colitis, open to volunteers
Ulcerative Colitis
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- TOPAZ-UC (NCT07186101)
- Testing
- LY4268989, Mirikizumab
- Where
- 147 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis, Inflammatory Bowel Diseases
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
The goal of this clinical trial is to learn if combined therapy with infliximab and ustekinumab works better than using these drugs alone in adult patients with ulcerative colitis.
- Trial name
- COMBO-UC (NCT06453317)
- Testing
- Infliximab, Ustekinumab
- Where
- Poland
- Volunteers
- 172 people
- Sponsor
- Medical University of Lodz
Ulcerative Colitis (UC)
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
- Trial name
- NCT07686081
- Testing
- Ponesimod
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vanda Pharmaceuticals
Colitis, Ulcerative
A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis
This study will look at how safe and tolerable different treatments are for adults who have moderate to severe ulcerative colitis (UC).
- Trial name
- PEGASUS (NCT07747467)
- Testing
- Aletekitug (GSK1070806)
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies…
- Trial name
- NCT06979336
- Testing
- RO7837195
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 224 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06764706
- Where
- 57 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AbbVie
Colitis, Ulcerative
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic…
- Trial name
- DUET ENCORE-UC (NCT07577856)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 318 sites in United States, Argentina and 31 more
- Volunteers
- 644 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).
- Trial name
- NCT05287126
- Testing
- Etrasimod
- Where
- 47 sites in United States, Japan and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Ulcerative Colitis (UC)
A Study for HSK47388 in Participants With Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy and safety of HSK47388 as therapy in participants with moderately to severely active ulcerative colitis .
- Trial name
- NCT07335055
- Testing
- HSK47388
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Ulcerative Colitis (UC)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
This study will evaluate the efficacy and safety of 627 in patients with UC.
- Trial name
- NCT07507513
- Testing
- 627
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Colitis, Ulcerative
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis
This goal of this sub-study is to learn how safe and tolerable the study drug, aletekitug (anti-IL-18), in participants with moderately to severely active ulcerative colitis (UC). This study is the sub-study of the platform trial.
- Trial name
- NCT07747480
- Testing
- Aletekitug
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- RISE UP (NCT07136116)
- Where
- 29 sites in Japan
- Volunteers
- 200 people
- Sponsor
- AbbVie
Inflammatory Bowel Diseases
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and…
- Trial name
- NCT06754891
- Testing
- 24mg bid TQH3906 capsule, 32mg TQH3906 capsule
- Where
- 30 sites in China
- Volunteers
- 135 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Colitis, Ulcerative
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
- Trial name
- NCT05076175
- Testing
- Ozanimod
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial comprising screening period, treatment period, and follow-up period.
- Trial name
- NCT07229950
- Testing
- HRS-7085
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Ulcerative Colitis
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- SUNSCAPE-2 (NCT07185009)
- Testing
- Duvakitug
- Where
- 171 sites in United States, Argentina and 29 more
- Volunteers
- 751 people
- Sponsor
- Sanofi
Ulcerative Colitis
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- MIGHTY (NCT07071519)
- Testing
- Risankizumab
- Where
- 73 sites in United States, Belgium and 14 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Crohn's Disease
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Background: Crohn s disease (CD) is an inflammatory bowel disease. It causes inflammation of the gut. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition.
- Trial name
- NCT03167437
- Testing
- Vorinostat, Ustekinumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Moderate-to-severe Ulcerative Colitis, Crohn's Disease (CD)
Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease
This is an open-label, Phase I, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05 in patients with moderate-to-severe ulcerative colitis…
- Trial name
- NCT07309744
- Testing
- RD06-05 CART Cell Infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colitis, Ulcerative
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis.
- Trial name
- ENDEAVOUR-UC (NCT06398626)
- Testing
- Etrasimod
- Where
- 29 sites in United States
- Volunteers
- 300 people
- Sponsor
- Pfizer